Pulmonary tuberculosis Type 2 diabetes mellitus Metformin Tuberculosis,
Conditions
Interventions
Patients who are newly diagnosed pulmonary tuberculosis and diagnosed type 2 diabetes mellitus which are exposed to metformin along period of study,Patients who are newly diagnosed pulmonary tuberculo
Treatment,Treatment
Exposed to metformin,Not exposed to metformin
Sponsors
Khon Kaen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 0 Years
Inclusion criteria
Inclusion criteria: Patients who are newly diagnosed pulmonary tuberculosis and enroll in the nested RCT “Efficacy of N-acetylcysteine in sputum smear conversion in pulmonary tuberculosis; multicenter open label pragmatic randomized controlled trial†- TCTR identification number is TCTR20190128002 Patients who diagnosed type 2 diabetes mellitus
Exclusion criteria
Exclusion criteria: There is no exclusion criteria in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sputum smear (AFB) conversion At the end of 2, 4, 8 and 12 weeks after anti-TB treatment event rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Doses of metformin that are associated with sputum smear conversion At the end of 2, 4, 8 and 12 weeks after anti-TB treatment event rate of sputum smear conversion at each dose,Adverse events Along period of study event rate,Hospital admission from any causes Along period of study event rate,Rate of multi-drug resistant tuberculosis Along period of study event rate | — |
Countries
Thailand
Contacts
Public ContactKanyanut Kasiansin
Department of Social Medicine, Khon Kaen Hospital
Outcome results
None listed